CM
AVDL

Capula Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Capula Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-19,742
Closed -$259K – 392
2024
Q3 		$259K Sell
19,742
-76,301
-79% -$1.16M ﹤0.01% 331
2024
Q2 		$1.35M Buy
+96,043
New +$1.57M 0.01% 125

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Capula Management's AVDL Position: Q4 2024 in Review

Capula Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2024, closing a stake of 19,742 shares — an estimated $259K sold.

Capula Management first reported a position in AVDL in Q2 2024 and held it in 2 quarters. The position peaked at $1.35M in Q2 2024. 159 funds tracked by Wall St. Rank hold AVDL as of Q4 2024.

  • Capula Management reported no remaining Avadel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capula Management sold 19,742 Avadel Pharmaceuticals shares in Q4 2024, an estimated $259K.
  • Capula Management first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Capula Management's Avadel Pharmaceuticals position peaked at $1.35M in Q2 2024.
  • 159 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2024.

Based on Capula Management's 13F filing for Q4 2024, filed 13 Feb 2025.